减毒活水痘疫苗在13岁及以上健康人群中的免疫原性与安全性:随机双盲对照研究
在中国13岁及以上健康人群中开展随机双盲对照试验,共纳入2398人。两剂测试疫苗与阳性对照疫苗按4、6或8周间隔接种后,抗体阳转率分别为79.55%和76.41%,GMT分别为1:162.07和1:160.04,均达到预设非劣效标准;10周间隔两剂方案阳转率为83.22%,GMT为1:160.38。安全性特征在各组间相似。
要点
- 两剂测试疫苗与阳性对照疫苗的阳转率差值为3.14%(95%CI:-0.69%,6.97%),达到非劣效标准。
- 两剂测试疫苗与阳性对照疫苗的GMT比值为1.013(95%CI:0.910,1.127),达到非劣效标准。
- 10周间隔两剂测试疫苗的阳转率为83.22%,GMT为1:160.38。
核心结论
- 由Sinovac(Dalian)生产的减毒活水痘疫苗在13岁及以上健康人群中显示出较高的免疫应答和更灵活的免疫程序,且未增加安全性风险。
研究设计与样本
- 在中国13岁及以上健康人群中开展的随机双盲对照临床试验,共纳入2398名参与者。
- 第一区块参与者按1:1随机分配接种两剂测试疫苗或阳性对照疫苗,间隔4、6或8周。
- 第二区块参与者按2:1随机分配接种两剂测试疫苗或安慰剂,间隔10周。
- 主要免疫原性终点为免疫后4周经荧光抗体膜抗原法(FAMA)检测的水痘带状疱疹病毒(VZV)抗体阳转率和GMT。
- 主要安全性终点为每剂接种后4周内不良事件发生率。
主要发现
- 两剂合并程序免疫后4周,测试组VZV抗体阳转率为79.55%,阳性对照组为76.41%,差值为3.14%(95%CI:-0.69%,6.97%)。
- 两剂合并程序免疫后4周,测试组GMT为1:162.07,阳性对照组为1:160.04,比值为1.013(95%CI:0.910,1.127)。
- 阳转率和GMT均达到预设非劣效标准。
- 10周间隔两剂测试疫苗方案在测试组中诱导的阳转率为83.22%,GMT为1:160.38。
- 测试组、阳性对照组和安慰剂组的安全性特征相似。
关键数值与推荐
- 两剂合并程序免疫后4周,测试组阳转率79.55%,阳性对照组76.41%,差值3.14%(95%CI:-0.69%,6.97%),达到非劣效标准。
- 两剂合并程序免疫后4周,测试组GMT 1:162.07,阳性对照组1:160.04,比值1.013(95%CI:0.910,1.127),达到非劣效标准。
- 10周间隔两剂测试疫苗方案在测试组中阳转率83.22%,GMT 1:160.38。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Vaccines for prevention against varicella are important for adolescents and adults, who have an increased risk of severe varicella. This study aimed to evaluate the immunogenicity and safety of a two-dose immunization schedule of a live-attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) in healthy adolescents and adults. METHODS: A randomized, double-blind, controlled clinical trial was conducted in healthy population aged ≥ 13 years old in China. Participants in block 1 were randomly assigned (1:1) to receive two doses of either the test vaccine or an active control vaccine, administered 4, 6 or 8 weeks apart. Participants in block 2 were randomly assigned (2:1) to receive two doses of test vaccine or placebo, administered 10 weeks apart. The primary immunogenicity endpoint was the seroconversion rates and GMTs of varicella zoster virus (VZV) antibodies measured by fluorescent-antibody-to-membrane-antigen (FAMA) 4 weeks post-immunization. The primary safety endpoint was the incidence of adverse reactions within 4 weeks after each dose. RESULTS: A total of 2398 participants were enrolled. The seroconversion rates of VZV antibodies were 79.55 % in the test group and 76.41 % in the active control group respectively 4 weeks after two doses of pooled schedule, with the difference of 3.14 % (95 %CI: -0.69 %, 6.97 %). The GMTs were 1:162.07 and 1:160.04 respectively, with the ratio of 1.013 (95 %CI: 0.910, 1.127). Both the seroconversion rates and GMTs reached the prespecified non-inferiority criteria. Two-dose schedule with an interval of 10 weeks could also induce high immune responses, with a seroconversion rate of 83.22 % and a GMT of 1:160.38 in the test group. Safety profiles were similar among the test group, active control group and placebo group. CONCLUSION: VarV, manufactured by Sinovac (Dalian), demonstrated higher immune response and better flexibility in the immunization schedule among heathy population aged 13 years and older, without increased safety risk.
引用
- Huang L, Chen Z, Song Y, et al. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study. Vaccine. 2023. PMID: 38057208. doi:10.1016/j.vaccine.2023.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。